Phase 2 EGFR Gene Mutation trials recruiting now

All EGFR Gene Mutation trials, every phase

Phase 2 EGFR Gene Mutation trials

• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
  NCT07548060 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
  NCT03175224 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
  NCT05503667 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
  NCT06071013 · Phase: Phase 1, Phase 2 · Ages: 20 Years to 70 Years · Sex: All (male and female) · 1 location
• Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
  NCT04322890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
  NCT06222489 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.